Last $0.55 USD
Change Today -0.07 / -11.29%
Volume 461.2K
IBIO On Other Exchanges
As of 8:04 PM 09/22/14 All times are local (Market data is delayed by at least 15 minutes).

ibio inc (IBIO) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/21/14 - $0.85
52 Week Low
05/27/14 - $0.24
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for IBIO INC (IBIO)

Related News

No related news articles were found.

ibio inc (IBIO) Related Businessweek News

No Related Businessweek News Found

ibio inc (IBIO) Details

iBio, Inc., a biotechnology company, focuses on the commercialization of its proprietary plant-based protein expression technologies in the United States and internationally. Its proprietary technologies include iBioLaunch, a transformative platform technology for the development and production of biologics; and iBioModulator, a technology platform that improves the potency and duration of the effect of prophylactic and therapeutic vaccines. The company’s product candidates include C1 Esterase Inhibitor, a preclinical stage plasma-derived protein; Alpha-Galactosidase, a preclinical orphan designation stage enzyme replacement; and Palivizumab, a preclinical stage monoclonal antibody for the therapeutic protein market. Its product candidates also comprise H1N1 Influenza and H5N1 Influenza viral disease vaccines that completed Phase I; Hookworm parasitic pathogen vaccine, which is in preclinical stage; and Human Papillomavirus therapeutic vaccine that is in preclinical stage. In addition, the company’s product candidates include Anthrax/Plague bacterial disease vaccine that is in preclinical stage; and Anthrax monoclonal antibody that is in preclinical stage for the Biodefense market. It has a collaboration agreement with Fraunhofer Center for Molecular Biology to perform research and development activities to develop the recombinant form of C1 esterase inhibitor; an alliance with GE Healthcare to commercialize its plant-based technologies for the manufacture of biopharmaceuticals and vaccines; a collaboration agreement granting FioCruz/Bio-Manguinhos a license to use its proprietary technology in connection with the development, manufacture, and commercialization of vaccine products; and a license and collaboration agreement enabling Caliber Biotherapeutics LLC to use its iBioLaunch platform in connection with the development of an undisclosed monoclonal antibody-based therapeutic protein for an oncology indication. The company is headquartered in Newark, Delaware.

9 Employees
Last Reported Date: 09/30/13

ibio inc (IBIO) Top Compensated Officers

Executive Chairman and Chief Executive Office...
Total Annual Compensation: $300.0K
Total Annual Compensation: $230.0K
Chief Scientific Officer
Total Annual Compensation: $200.0K
Compensation as of Fiscal Year 2013.

ibio inc (IBIO) Key Developments

Thomas A. Medsger Joins iBio, Inc.'s Clinical Advisory Board

iBio, Inc. has appointed Thomas A. Medsger Jr., M.D., to its clinical advisory board. Dr. Medsger is an expert in systemic sclerosis and localized scleroderma. Dr. Medsger will provide iBio with guidance on the further development and commercialization of the company's novel drug candidate, IBIO-CFB03, for idiopathic pulmonary fibrosis (IPF), systemic sclerosis (SSc), and other fibrotic diseases.

iBio, Inc. Forms Marketing Collaboration with Kanematsu Chemicals Corporation to Target Japanese Market

iBio, Inc. and Kanematsu Chemicals Corporation, part of Kanematsu Corporation have entered into a collaboration agreement under which Kanematsu Chemicals Corporation will market the novel iBio Launch platform in Japan. The collaboration combines iBio's plant-based expression system and expertise for rapid, reliable and economical development and production of biological vaccines and therapeutics, with the marketing reach and regional expertise of the life science group from Kanematsu Chemicals Corporation. Japan commands 9% of global biologics sales (led only by the U.S. and the EU), a global market that is expected to grow to over $220 billion by 2019, according to TriMark Publications. Biologics can be categorized in three main groups: monoclonal antibodies, other therapeutic proteins, and vaccines. The iBio Launch platform has been validated for production of each of these biologics categories. The iBio Launch platform can enable companies producing either novel biologics or bio similars to achieve competitive advantages over other expression systems due to its various attributes, including lower costs and scalability.

iBio, Inc. Appoints J. Terrill Huggins to its Clinical Advisory Board

iBio, Inc. announced that it has appointed J. Terrill Huggins, M.D. to its clinical advisory board. The board of science and medical experts is assisting iBio in its clinical and product strategy. Dr. Huggins is a leading clinical investigator in the field of idiopathic pulmonary fibrosis (IPF), and has been the principal investigator or co-principal investigator in more than 20 IPF clinical trials. Dr. Huggins is associate professor of medicine in the Division of Pulmonary, Critical Care, Allergy, and Sleep Medicine at the Medical University of South Carolina. He also serves as the director of the Interstitial Lung Disease Program at MUSC. His research interests center on interstitial lung disease and particularly IPF. Over the past 10 years, MUSC has become one of the larges IPF clinical trials programs in the U.S., and was the high enrolling site for both recently completed Phase III trials studying the efficacy of pirfenidone and nintenanib in the treatment of IPF. Dr. Huggins has authored 33 original manuscripts, 100 plus abstracts and national presentations, and has authored 20 book chapters.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IBIO:US $0.55 USD -0.07

IBIO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for IBIO.
View Industry Companies

Industry Analysis


Industry Average

Valuation IBIO Industry Range
No financial data is available for IBIO.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IBIO INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at